The interface between patent law and competition law constitutes one of the most complex challenges in contemporary economic law. These two branches of law pursue apparently contradictory objectives: intellectual property law protects a particular interest by guaranteeing the creator that they can profit from their creation by prohibiting any unauthorised person from infringing their exclusive rights, while competition law aims to prevent undesirable market behaviour and, in particular, abuses of market power.<\/p>\n
There is a close link between patent rights and competition, which has two characteristics. On the one hand, patent law aims to prevent the copying or imitation of patented products and thus complements competition policy by promoting balanced market behaviour. On the other hand, competition law can limit patent rights by preventing patent holders from abusing their rights.<\/p>\n
This fundamental tension requires constant arbitration. Therefore, a balance must be struck between competition policy and patent rights, and this balance must prevent abuses of patent rights, without negating the benefits intended by the patent system when these rights are used appropriately.<\/p>\n
Patents confer exclusive rights which, whilst recognised, can lead to anti-competitive practices. Such practices are all the more frequent and damaging when the company holding an intellectual property right also holds a dominant position in the relevant market.<\/p>\n
French and European law particularly penalise agreements which have the object or effect of distorting competition in a market.<\/strong> Agreements concerning the exploitation of inventions are not, by their nature, exempt from the application of competition law.<\/p>\n The Servier affair perfectly illustrates the potential abuses. The validity of patent 947 having been challenged by several generic laboratories preparing to enter the perindopril market, Servier concluded settlement agreements with the latter, under which the generics agreed not to challenge the patent and to stay out of the market until its expiry, in exchange for financial compensation from Servier.<\/p>\n In 2014, the Commission imposed fines totalling \u20ac427.7 million on Servier and five generic laboratories, considering that the agreements in question, under the guise of a settlement, had the actual object and effect of restricting competition. In 2024, the Court of Justice of the European Union confirmed that so-called \u00abpay-for-delay\u00bb agreements constitute restrictions of competition by object.<\/p>\n The essential facilities doctrine, originally developed to enable access to infrastructure, was first applied to intellectual property rights in the Magill case of 6 April 1995. This doctrine imposes strict conditions: a refusal of access lacking objective justification, emanating from one or more companies in a dominant position in an upstream market, concerning a facility indispensable for carrying on an activity in a downstream market, which cannot be replicated under reasonable conditions, thereby preventing the emergence of a new product.<\/p>\n The application of this theory to intellectual property rights has seen significant evolution. The IMS judgment led to a shift in the application of the essential facility doctrine in favour of firms operating in the same market, and offering the same service, which considerably weakens the novelty criterion.<\/p>\n In the IMS Health case, the American company IMS Health had patented a modular database based on German postal codes. To compete more effectively with IMS in this market, the company NDC wished to gain access to this database, which had become a market standard. Faced with IMS's refusal to grant it a licence for exploitation, NDC seized the Commission for abuse of a dominant position.<\/p>\n This is particularly the case when intellectual property law consists of a essential patent for a standard<\/strong> (BEN), with competitors then having no choice but to use the patent if they wish to implement a product that complies with the standard.<\/p>\n A standard-essential patent is a patent that is \u00abessential to practice a given standard\u00bb and whose implementation is \u201cindispensable for any competitor intending to manufacture products conforming to the standard to which it is linked\u201d. These patents are subject to specific obligations: a FRAND licence means that the licence must be: Fair (the licence must not contain terms that unduly restrict competition), Reasonable (the licence fee must not be prohibitive), Non-Discriminatory (any third party must be treated in the same way).<\/p>\n The holding of an SEP by a company in a dominant position and the refusal to grant FRAND licences to a third party are at the origin of the CJEU's decision of 16 July 2015, in which the obligations incumbent on both the SEP holder and the potential licensee were clarified.<\/p>\n This case law establishes a strict procedural framework for infringement actions involving standard-essential patents, balancing the rights of the patent holder and the needs of competition.<\/p>\n These criteria undoubtedly give competition authorities a wide margin of discretion to assess whether conduct constitutes an abuse. From when, indeed, can a good be considered truly necessary or new?<\/p>\n The Court confirmed that these settlement agreements constituted restrictions of competition by object, contrary to single market law by preventing market entry by competitors. It recalls the case law developed by the European Court which \u00ab sanctions the abnormal use of intellectual property rights<\/strong> \u00bb.<\/p>\n The boundary between patents and competition law continues to evolve in the face of contemporary technological challenges. Competition authorities must strike a balance between the expected benefits from the granting of a licence, potential innovations through the disclosure of information, whilst taking into account the impact of granting such a licence on innovation.<\/p>\n This constant tension between protecting innovation and preserving competition requires constant vigilance on the part of regulatory authorities. Case law evolution shows a trend towards increased scrutiny of patent holders' practices.<\/strong>, particularly when they hold a dominant position, while preserving the incentives to innovate that justify the very existence of the patent system.<\/p>\n The balance remains fragile and must be constantly reassessed in light of technological and economic developments, particularly in high-tech sectors where standards-essential patents are playing an increasingly important role in market structuring.<\/p>","protected":false},"excerpt":{"rendered":" L’articulation entre le droit des brevets et le droit de la concurrence constitue l’un des d\u00e9fis les plus complexes du droit \u00e9conomique contemporain. Ces deux branches du droit poursuivent des objectifs apparemment contradictoires : le droit de la propri\u00e9t\u00e9 intellectuelle prot\u00e8ge un int\u00e9r\u00eat particulier en garantissant au cr\u00e9ateur qu’il pourra tirer profit de sa cr\u00e9ation […]<\/p>\n","protected":false},"author":3,"featured_media":10725,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16],"tags":[],"class_list":["post-10718","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-brevets"],"acf":[],"yoast_head":"\nThe Servier case: a textbook example of \u00abpay-for-delay\u00bb agreements\u00bb<\/h3>\n
The essential facilities doctrine applied to patents<\/h2>\n
The application criteria<\/h3>\n
Jurisprudence developments: from Magill to IMS Health<\/h3>\n
Standard essential patents: a specific challenge<\/h2>\n
The FRAND regime<\/h3>\n
The Huawei v. ZTE case<\/h3>\n
Contemporary challenges and future prospects<\/h2>\n
The increasing complexity of criteria<\/h3>\n
The impact of settlement agreements<\/h3>\n
The future challenges of this partnership<\/h2>\n